<DOC>
	<DOCNO>NCT01835431</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North South America . The aim trial investigate efficacy safety insulin degludec/insulin aspart daily plus insulin aspart remain meal child adolescent type 1 diabetes mellitus .</brief_summary>
	<brief_title>A Trial Investigating Efficacy Safety Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart Remaining Meals Versus Insulin Detemir Once Twice Daily Plus Meal Time Insulin Aspart Children Adolescents With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Informed consent obtain trial related activity . Trial related activity procedure carry part trial , include activity determine suitability trial Subjects diagnose type 1 diabetes mellitus HbA1c equal 11.0 % Known hypoglycaemic unawareness recurrent severe hypoglycaemic event judge investigator More 1 episode diabetic ketoacidosis require hospitalisation within last 3 month prior Visit 1 ( Screening ) Any chronic disorder significant concomitant disease , investigator 's opinion might jeopardise subject 's safety compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>